Trichomonas vaginalis screening and prevention in order to impact the HIV pandemic: Isn't it time we take this infection seriously?

Infectious Disease Reports

Volumn 3, Issue 1, 2011, Pages 12-14

  Lazenby, Gweneth B ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

HIV prevention; Human Immunodeficiency Virus (HIV); Sexually transmitted infections (STIs); Trichomonas vaginalis

Indexed keywords

METRONIDAZOLE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TINIDAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERMETHOD COMPARISON; MIXED INFECTION; NUCLEIC ACID AMPLIFICATION; PELVIC INFLAMMATORY DISEASE; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TREATMENT DURATION; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; URETHRITIS; UTERINE CERVICITIS; VAGINITIS; VERTICAL TRANSMISSION; VIRUS ATTACHMENT; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION; VIRUS VIABILITY;

EID: 79955945558     PISSN: None     EISSN: 20367449     Source Type: Journal    
DOI: 10.4081/idr.2011.e4     Document Type: Review

References (50)

1. Croce F, Piconi S, Atzeni F, et al. HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity. Clin Exp Rheumatol 2008;26:S48-52.
2. Guenthner PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun 2005;73:4155-60.
3. Laga M, Manoka A, Kivuvu M, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
4. Sexton J, Garnett G, Rottingen JA. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005;32:351-7.
5. Draper D, Donohoe W, Mortimer L, Heine RP. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. J Infect Dis 1998;178:815-9.
6. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000;27:284-8.
7. Pepin J, Plummer FA, Brunham RC, et al. The interaction of HIV infection and other sexually transmitted diseases: an opportunity for intervention. AIDS 1989;3:3-9.
8. Mertens TE, Hayes RJ, Smith PG. Epidemiological methods to study the interaction between HIV infection and other sexually transmitted diseases. AIDS 1990;4:57-65.
9. Levine WC, Pope V, Bhoomkar A, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998;177:167-74.
10. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997;349:1868-73.
11. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009;36:11-6.
12. Van Der Pol B, Williams JA, Orr DP, et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005;192:2039-44.
13. Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008;21:56-64.
14. Sena AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007;44:13-22.
15. Shafir SC, Sorvillo FJ, Smith L. Current issues and considerations regarding trichomoniasis and human immunodeficiency virus in African-Americans. Clin Microbiol Rev 2009;22:37-45.
16. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis 2004;31: 547-51.
17. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001;28: 579-97.
18. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007;195:698-702.
19. Van der Pol B. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 2007;44:23-5.
20. Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African-Americans. Emerg Infect Dis 2001;7:927-32.
21. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIVInfected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003;30:839-43.
22. Spinillo A, Zara F, Gardella B, et al. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 2005;192:774-9.
23. Borchardt KA, al-Haraci S, Maida N. Prevalence of Trichomonas vaginalis in a male sexually transmitted disease clinic population by interview, wet mount microscopy, and the InPouch TV test. Genitourin Med 1995;71:405-6.
24. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007;45:1319-26.
25. Joyner JL, Douglas JM Jr, Ragsdale S, et al. Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic. Sex Transm Dis 2000;27:236-40.
26. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002;34:1406-11.
27. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008;46:994-9.
28. Price MA, Miller WC, Kaydos-Daniels SC, et al. Trichomoniasis in men and HIV infection: data from 2 outpatient clinics at Lilongwe Central Hospital, Malawi. J Infect Dis 2004;190:1448-55.
29. Jackson DJ, Rakwar JP, Bwayo JJ, et al. Urethral Trichomonas vaginalis infection and HIV-1 transmission. Lancet 1997;350: 1076.
30. Cu-Uvin S, Hogan JW, Warren D, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIVseronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 1999;29:1145-50.
31. Atkins MC, Carlin EM, Emery VC, et al. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases. BMJ 1996;313: 341-2.
32. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001;183:1017-22.
33. Watson-Jones D, Mugeye K, Mayaud P, et al. High prevalence of trichomoniasis in rural men in Mwanza, Tanzania: results from a population based study. Sex Transm Infect 2000;76:355-62.
34. Midlej V, Benchimol M. Trichomonas vaginalis kills and eats--evidence for phagocytic activity as a cytopathic effect. Parasitology;137:65-76.
35. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-601.
36. Hobbs MM, Kazembe P, Reed AW, et al. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999;26:381-7.
37. Krieger JN, Verdon M, Siegel N, et al. Risk assessment and laboratory diagnosis of trichomoniasis in men. J Infect Dis 1992;166:1362-6.
38. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep;59:1-110.
39. Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol 2006;44:366-73.
40. Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004;2:67-74.
41. Kissinger P, Mena L, Levison J, et al. A Randomized Treatment Trial: Single Versus 7 Day Dose of Metronidazole for the Treatment of Trichomonas Vaginalis among Hiv-Infected Women. J Acquir Immune Defic Syndr;55:565-571.
42. Latif AS, Mason PR, Marowa E. Urethral trichomoniasis in men. Sex Transm Dis 1987;14:9-11.
43. Weston TE, Nicol CS. Natural History of Trichomonal Infection in Males. Br J Vener Dis 1963;39:251-7.
44. Watt L, Jennison RF. Incidence of Trichomonas vaginalis in marital partners. Br J Vener Dis 1960;36:163-6.
45. Catterall RD, Nicol CS. Is trichomonal infestation a venereal disease? Gynaecologia 1960;149:87-92.
46. Catterall RD. Diagnosis and treatment of trichomonal urethritis in men. Br Med J 1960;2:113-5.
47. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003;52:1-24.
48. Sorvillo F, Kovacs A, Kerndt P, et al. Risk factors for trichomoniasis among women with human immunodeficiency virus (HIV) infection at a public clinic in Los Angeles County, California: implications for HIV prevention. Am J Trop Med Hyg 1998;58:495-500.
49. Lichtenstein B, Desmond RA, Schwebke JR. Partnership concurrency status and condom use among women diagnosed with Trichomonas vaginalis. Womens Health Issues 2008;18:369-74.
50. Miller M, Liao Y, Gomez AM, et al. Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs. J Infect Dis 2008; 197:503-9.